Based in the Netherlands, VirXcel is a startup.
VirXcel develops innovative antiviral treatments using macrocyclic peptides that target conserved viral protein sites, focusing initially on intranasal therapeutics to prevent and mitigate respiratory infections like COVID-19.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.